(UroToday.com) The Game-Changing session at the European Association of Urology’s (EAU) 2021 virtual annual meeting included a discussion by Dr. Alberto Breda of the phase 3 KEYNOTE-564 clinical trial. Dr. Breda notes that based on several failed tyrosine kinase inhibitor (TKI) trials, the EAU guidelines do not recommend adjuvant therapy (sorafenib, pazopanib, everolimus, girentuximab, axitinib, or sunitinib) for high-risk renal cell carcinoma (RCC) given a lack of survival benefit.